80 results about "Brain Thrombus" patented technology

The invention relates to a three-stage brain-controlled upper limb rehabilitation method combining steady-state visual evoked potential and mental imagery (MI). The method comprises the following steps: (1) the first stage of VR video guidance training: a patient is made to be familiar with upper limb rehabilitation movements through VR video guidance; (2) the second stage of VR-SSVEP training: the patient needs to concentrate to observe pictures that represent different upper limb movements and flicker with a specific frequency, EEG signals of the patient are collected in real-time to analyzeintentions of the patient, and visual feedback is provided to the patient through VR animation to make the patient learn to concentrate; and (3) the third stage of VR-MI training: EEG signals of theleft and right upper limbs of the patient during MI are collected during off-line training, and a mental imagery intention recognition model is established. The EEG signals of mental imagery of the patient are analyzed according to the model during online training, movement intentions of the patient are recognized, and movements of a 3D character in an interface are controlled in real time, so that brain central nerve remodeling is facilitated through MI. The method exhibits a good immersion property, enables active rehabilitation to be realized, enables rehabilitation to proceed step by step,and is a new method for upper limb rehabilitation of a cerebral stoke patient.

The invention discloses IncRNA markers of cerebral arterial thrombosis. The IncRNA markers are LINC00189 and LOC105376014, wherein the expression of the LINC00189 is up-regulated in a patient with cerebral arterial thrombosis, and the expression of the LOC105376014 is down-regulated in the patient with cerebral arterial thrombosis. The IncRNA markers can be used for early diagnosis of cerebral arterial thrombosis and has relatively high sensitivity and specificity.

The invention relates to a Parischnogaster spp vespo bee venom polypeptide effective part and preparation and medical application thereof. Specifically, the effective part is prepared by dialyzing in the Parischnogaster spp rough bee venom with a dialysis membrane with molecular weight cutoff of 25KDa, and drying the eluate by means of freeze drying or concentration under reduced pressure. By a series of pharmacodynamic experiments, the inventor verifies that the biotoxin polypeptide effective part and transdermal absorption preparation thereof have the effects of remarkably preventing and treating generation of cerebral thrombus, recovering capacity for action of animal with cerebral palsy and relieving ischemic brain injury, have stronger pharmacodynamic performance than the first-line medicines, such as plavix and Xingnaojing, can be expectedly used for preparing cardiovascular and cerebrovascular disease prevention and treatment biochemical drugs for preventing and treating ischemic cardiovascular and cerebrovascular diseases, such as myocardial infarction, cardiovascular thrombosis, cerebral thrombosis, cerebral infarction and acute/chronic cerebral apoplexy, and sequelae caused by cerebral infarction injury, such as hemiplegia, hemidysesthesia, hemianopsia, facial-tongue paralysis, aphasia and general paralysis.

The invention relates to the technical field of thrombus or blood coagulation related disease detection, in particular to a biomarker and application thereof in thrombus or blood coagulation related disease detection. The marker comprises a blood coagulation factor 13 activating peptide (FXIIIAP) or/and a blood coagulation factor 13 A subunit (FXIIIA). The detection kit provided by the invention comprises a capture antibody and a detection antibody, and is a specific antibody prepared by taking FXIIIAP as an antigen. The biomarker disclosed by the invention has a good application prospect in the aspect of quickly screening and diagnosing thrombus or blood coagulation related diseases including cerebral apoplexy, can greatly improve the sensitivity and specificity of existing diagnosis, speculates the thrombus formation time and degree, and can predict the severity and prognosis of the diseases.

The invention belongs to the technical field of gene mutation detection, and discloses a CRISPR (clustered regularly interspaced short palindromic repeats)-based kit for detecting a cerebral apoplexy related TYMS gene, the kit comprises mutant crDNA (deoxyribonucleic acid) or mutant crRNA (ribonucleic acid) designed for rs699517 and rs2790 loci of the TYMS gene, and the sequence of the mutant crDNA or the mutant crRNA is shown as SEQ ID NO.1-4. By combining a CRISPR-cas12a system, whether gene mutation of the rs699517 and/or rs2790 loci of the TYMS gene exists in a sample to be detected or not can be determined, and whether the gene mutation of the rs699517 and/or rs2790 loci of the TYMS gene The kit has the advantages of high specificity, high accuracy, high detection speed and the like, and has wide application prospects.

The invention relates to an application of a composition of hydroxysafflor yellow A and tenuigenin in preparation of a medicine for treating cerebral arterial thrombosis. The medicine effect of hydroxysafflor yellow A and tenuigenin for improving cerebral arterial thrombosis is researched for the first time, the result shows that the degree of encephaledema can be reduced and the volume of cerebral infarction can be reduced through combined use of hydroxysafflor yellow A and tenuigenin, and the improvement effect on encephaledema and the improvement effect on cerebral infarction are obviously superior to those of hydroxysafflor yellow A and tenuigenin which are independently used; and the obvious synergistic effect is realized. The invention provides a novel medicine for treating cerebral arterial thrombosis.

The invention discloses a polypeptide with nNOS-Capon uncoupling activity and an application of the polypeptide. The polypeptide is characterized in that a structural general formula of the amino acidsequence is Che-Xaa1-Xaa2-Xaa3-Val, wherein the Che is equal to N-Cyclohexylethyl, the Xaa1 is equal to Ala or Gly, the Xaa2 is equal to Glu, Glu (OMe), Asp or Asp (OMe), and the Xaa3 is equal to modified or natural amino acid. The polypeptide has nNOS-Capon uncoupling activity, and can be used as a neuroprotective agent for treating cerebral arterial thrombosis. The invention provides a fluorescence polarization method (FP) for rapidly screening nNOS-Capon uncoupling activity in vitro. The polypeptide screened by the FP method has an obvious neuroprotective effect on a rat cerebral ischemiareperfusion model (MACO).

The invention discloses an application of elemicin in preparation of a medicine for preventing and treating cerebral arterial thrombosis. The animal experiments prove that the compound elemicin can effectively improve the neurological function score, reduces cerebral infarction area, and improves relevant antioxidant capacity indexes; and the results show that the compound elemicin has a protective effect on cerebral ischemia-reperfusion injury, can effectively prevent and treat cerebral injury caused by cerebral ischemia, and provides a new research direction for the preparation of cerebral ischemia injury related drugs; the invention also discloses the medicine for preventing and treating cerebral arterial thrombosis, which comprises elemicin and pharmaceutically acceptable auxiliary materials, the nerve function can be effectively improved, the cerebral infarction area is reduced, oxidative damage is improved, and the application effect is excellent.

The invention relates to a hydrogen sulfide donor, a preparation method and applications thereof, and belongs to the technical field of medicines, wherein the hydrogen sulfide donor is chemically named S-(4-fluorobenzyl)-N-(3,4,5-trimethoxybenzoyl)-L-cysteine methyl ester, and has a chemical structural formula represented by a formula (I). According to the invention, the hydrogen sulfide donor (MTC) can effectively treat cerebral arterial thrombosis diseases by activating a PI3K/AKT pathway, inhibiting a mitochondrial apoptosis signal pathway, reducing endoplasmic reticulum stress, activatingan ERK-MEK signal pathway, increasing the survival rate of nerve cells or protecting various treatment targets of nerve cell ischemic injury.

The invention relates to a polypeptide valid target in Ropalidia fasciata insects and application thereof in preventing and treating cerebral thrombosis. The valid target is prepared by the following steps: dialyzing Ropalidia fasciata crude bee venom with a 30kDa dialysis membrane, and carrying out freeze-drying or vacuum concentration and drying on the dialysis solution. A series of pharmacodynamic experiments by people prove that the biotoxin polypeptide valid target and a transdermal absorption preparation thereof have obvious effects on preventing and treating cerebral thrombosis, restoring mobility of animals with cerebral palsy, preventing and treating platelet accumulation and relieving ischemic brain injury, and have better pharmacodynamic performance than Plavix, Xingnaojing injection and other first-tier medicines. The valid target is expected to be used for preparing innovative biochemical medicines for treating cardiovascular and cerebrovascular diseases and for preventing and treating ischemic cardiovascular and cerebrovascular diseases, such as myocardial infarction, cardiovascular thrombosis, cerebral thrombosis, cerebral infarction, acute/chronic cerebral apoplexy, and sequelae caused by cerebral infarction injury, including hemiplegia, hemidysesthesia, hemianopsia, facioplegia, paralysis lingualis, aphasia, pamplegia and the like.

The invention relates to the field of disease detection, and particularly discloses a specific antibody for detecting the blood brain barrier early injury of cerebral arterial thrombosis and application of the antibody. The antibody is characterized in that the antibody only specifically recognizes KTRRKMDRYDKSNIL in a degradation fragment of occludin protein, and does not recognize occludin total-length protein. Therefore, the antibody can be used for specifically detecting the blood brain barrier early injury of the cerebral arterial thrombosis, and can eliminate the influence of the occludin total-length protein in serum on a detection result, so that the specificity and the accuracy of detecting the blood brain barrier early injury of the cerebral arterial thrombosis are obviously improved.

The invention relates to an application of CART to preparation of ischemic brain injury neuroprotective agent medicine, and the CART is prepared into an injection preparation. At present, an effective neuroprotective agent for cerebral arterial thrombosis does not exist clinically, CART is one of few peptide substances which are found at present and can pass through a blood-brain barrier as an endogenous small-molecule neuropeptide, the CART firstly regulates and controls the synaptic plasticity of ischemic neurons, the protein gene expression is regulated and controlled by regulating and controlling cytoskeleton activity, the ischemic neuron synapsin expression and the number of synapses are increased, and neuron axon growth is promoted; secondly, neuronal regeneration is promoted, nerve cell apoptosis is reduced, and ischemic brain injury is relieved. The CART not only can regulate and control the synaptic plasticity of ischemic neurons, but also can promote the regeneration of neurons, and simultaneously acts on a plurality of targets in the pathological process of ischemic brain injury, so that the dual effects exactly accord with the current treatment strategy of cerebral arterial thrombosis.

The invention belongs to the technical field of biomedicines, and particularly relates to a zebra fish cerebral arterial thrombosis model, a construction method and application. Beta-amyloid protein liquid with the concentration of 0.01-0.05 mu g/ml is injected into the head of a normally developed adult zebra fish according to the injection amount of 1 mu L/kg of body weight, the zebra fish is placed into normal saline for 20-40 min after injection, and then the zebra fish is transferred into feeding liquid containing an inducer for feeding for 4-7 d; and the inducer is a soluble lanthanum compound or a soluble lead compound. The cerebral arterial thrombosis model of cerebellar obstruction is successfully constructed, and a foundation is laid for research and development of cognitive function nerve injury related drugs.

The invention discloses a heterocyclic compound and application thereof. The invention provides a heterocyclic compound shown as a formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compound can be used as an FXIa inhibitor; the compound can be used for preparing anticoagulant drugs and preventing and/or treating thrombus, such as thrombotic diseases of a human body, including cerebral arterial thrombosis and deep venous thrombosis diseases.

The invention discloses application of medioresinol in preparation of a drug for preventing or treating the cerebral injury and a pharmaceutical composition thereof. The invention provides applicationof medioresinol in preparation of a drug for preventing or treating the cerebral injury for the first time; the medioresinol has an obvious effect on prevention or treatment of the cerebral injury, especially the cerebral injury caused by the cerebral arterial thrombosis; and the cerebral injury caused by the cerebral arterial thrombosis can be obviously reduced. The experiment discovers that themedioresinol has an effect of inhibiting brain microvascular endothelial cell damage caused by oxygen-glucose deprivation and is capable of obviously reducing the permeability of a blood brain barrier under oxygen-glucose deprivation. The medioresinol can reduce the volume of cerebral infarction under middle cerebral artery occlusion remarkably. The pharmaceutical composition containing the medioresinol can become a novel drug for preventing and/or treating the cerebral injury and is used for treating various cerebrovascular diseases including cerebral arterial thrombosis.

The invention relates to medical application of crebanine in preventing or treating neurodegenerative diseases, belongs to the field of medicines, and particularly relates to crebanine for improving cerebral arterial thrombosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or Huntington's disease. Pharmacological experiments show that the crebanine has a good treatment effect on cerebral arterial thrombosis caused by middle cerebral artery ischemia reperfusion and has a remarkable treatment effect on Alzheimer's disease model mice caused by LPS, and therefore, the crebanine can be used for preparing the medicine for preventing or treating neurodegenerative diseases.

The invention relates to application of cobimetinib in preparation of a medicine for treating ischemia/reperfusion injury and a cell protection medicine. The cobimetinib is used for preparing the medicine for treating ischemia/reperfusion injury, especially the medicine for treating myocardial cell and nerve cell injury, and the medicine has a good protection effect on heart and cerebral ischemia/reperfusion injury (myocardial infarction and cerebral arterial thrombosis), and can obviously relieve the heart and cerebral ischemia/reperfusion injury.

The invention discloses an ischemic cerebral apoplexy in-vitro low-temperature drainage device and target spot interrupter, which comprises a device main body, a drainage device, a continuous flushing device, a cooling device and a target spot interrupter, and is characterized in that the drainage device, the continuous flushing device, the cooling device and the target spot interrupter are all positioned on the device main body; the left end part of the washing pipe is communicated with the cooling inner pipe, the target spot current breaker is fixed on the drainage pipe of the drainage device, and the target spot current breaker comprises a left connector, a current breaking main body and a right connector. The device is simple in principle and convenient to use, infection can be effectively prevented through the target cutoff device and the continuous flushing device, and intraoperative operation is facilitated.

The invention discloses a nervous injury repair promoting active polypeptide HW-P3 derived from a sun frog and application of the nervous injury repair promoting active polypeptide HW-P3. And the amino acid sequence of the polypeptide HW-P3 is FLPAAICLVIKTC. The application refers to the application in preparation of drugs for treating or preventing brain nerve injury. The invention provides a novel polypeptide HW-P3 derived from the skin of a sun frog. The polypeptide HW-P3 has the activity of promoting nerve injury repair in vivo and in vitro. And the HW-P3 only has 13 amino acids, is easy to synthesize and low in cost, provides a new approach for development of nerve injury repair drugs, and also provides a new direction for development of cerebral arterial thrombosis treatment drugs.

The invention refers to a kind of Chinese traditional medicine preparation; it is rheumatism eliminating and thrombus dissolving medicine which has particular effect to rheumatoid, brain thrombus and the sequela, grout. It uses yaerqin as materials to produce capsule, tablet, particles, and normal Chinese traditional medicine preparation. The process is simple, the period of treatment is short, it is quick-acting, and cure rate is high.